Carotid intima-media thickness in children treated with growth hormone
| Autor: | Thomas Reinehr, Rainer Wunsch, Caroline Knop, Barbara Wolters, Nina Lass |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Endocrinology Diabetes and Metabolism Turner Syndrome Growth hormone Carotid Intima-Media Thickness Pubertal stage Endocrinology Internal medicine Turner syndrome medicine Humans SHOX Deficiency cardiovascular diseases Risk factor Child Growth Disorders Human Growth Hormone business.industry Atherosclerosis medicine.disease Carotid Arteries Blood pressure Intima-media thickness Pediatrics Perinatology and Child Health cardiovascular system Small for gestational age Female business |
| Zdroj: | Journal of Pediatric Endocrinology and Metabolism. 28 |
| ISSN: | 2191-0251 0334-018X |
| DOI: | 10.1515/jpem-2014-0180 |
| Popis: | BACKGROUND There is an ongoing discussion whether high doses of growth hormone (GH) may lead to cardiovascular diseases. Therefore, we studied the relationships between GH treatment and carotid intima-media thickness (cIMT), which is predictive of the development of atherosclerosis. METHODS We measured cIMT in 38 children with supraphysiological doses of GH (mean age 10.9 ± 2.2 years; 47% male; GH indication: small for gestational age, n = 31; Turner syndrome, n = 5; SHOX deficiency, n = 2) and in 38 age- and gender-matched healthy children without GH treatment. Furthermore, we examined cIMT in 61 children with physiological doses of GH (mean age 12.0 ± 3.1 years; 64% male; GH indication: GH deficiency) and in 61 age- and gender-matched healthy children without GH treatment. Moreover, we analyzed blood pressure, lipids, HbA1c, IGF-1, and IGFBP-3 in children treated with GH. RESULTS The cIMT levels did not differ significantly between children with and without GH treatment either in high-dose GH treatment or in physiological GH doses. In backwards linear regression analyses, cIMT was significantly related to HbA1c, but not to age, gender, BMI, pubertal stage, indication of GH treatment, duration or doses of GH treatment, IGF-1, IGFBP-3, or to any cardiovascular risk factor. CONCLUSIONS We found no evidence that GH treatment is associated with changes in cIMT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|